EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Preanalytical stability of plasma/serum brain‐derived tau

Fernando Gonzalez-Ortiz, Alexandre Dias, Michael Turton, Rui Magalhães, Przemysław R Kac, Manuel Correia, Peter Harrison, Henrik Zetterberg, Luís F Maia, Kaj Blennow, Thomas K Karikari iD

Alzheimer's & Dementia · 2023-10 · 19 (10) · 4764-4770

DOI: 10.1002/alz.13156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 26.05.2023. Verfasst von Fernando Gonzalez-Ortiz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg,…. Hauptthemen laut MEDLINE: Alzheimer Disease, Ischemic Stroke. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NIH HHS, Alzheimer's Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION We investigated the effects of matrix type and reagent batch changes on diagnostic performances and longitudinal trajectories of brain‐derived tau (BD‐tau). METHODS We evaluated (i) Cohort 1: paired EDTA plasma and serum from Alzheimer biomarker‐positive older adults versus controls ( n = 26); and (ii) Cohort 2: n = 79 acute ischemic stroke patients with 265 longitudinal samples across four time points. RESULTS In Cohort 1, plasma and serum BD‐tau were strongly correlated (rho = 0.96, p < 0.0001) with similar diagnostic performances (AUCs >99%) and correlations with CSF total‐tau (rho = 0.93–0.94, p < 0.0001). However, absolute concentrations were ∼40% higher in plasma versus serum. In Cohort 2, first and repeated BD‐tau measurements showed a near‐perfect correlation (rho = 0.96, p < 0.0001), with no significant between‐batch concentration differences. In longitudinal analyses, substituting ∼10% of the first‐run concentrations for the remeasured values showed overlapping estimated trajectories without significant differences at any time point. DISCUSSION BD‐tau has equivalent diagnostic accuracies, but non‐interchangeable absolute concentrations, in plasma versus serum. Furthermore, the analytical robustness is unaffected by batch‐to‐batch reagent variations. Highlights Brain‐derived tau (BD‐tau) is a novel blood‐based biomarker that quantifies tau protein of CNS origin. Effects of preanalytical handling procedures on the quality and reproducibility of BD‐tau measures are unknown. In two cohorts of n = 105 participants, we compared BD‐tau concentrations and diagnostic performances in paired plasma and serum samples, and evaluated impacts of batch‐to‐batch reagent variations. Paired plasma and serum showed equivalent diagnostic performances to separate amyloid‐positive AD from amyloid‐negative controls, indicating both can be used independently. Repeated measurements and longitudinal trajectories of plasma BD‐tau were unaffected by batch‐to‐batch reagent variation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseIschemic StrokeHumansAgedtau ProteinsAmyloid beta-PeptidesReproducibility of ResultsBrainBiomarkers

Stichwörter der Autor:innen

Alzheimer's diseaseacute ischemic strokebrain-derived tauplasmapreanalytical handlingserumtotal tau

Substanzen

tau ProteinsAmyloid beta-PeptidesBiomarkers

Autor:innen und Institutionen

  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Institute for Research & Innovation in Health (i3S), Porto, Portugal.
  • Bioventix Plc, Farnham, Surrey, UK.
  • Population Studies, Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.
  • Department of Neurology, Centro Hospitalar Universitário do Porto, Porto, Portugal.

ORCID-Profile: Thomas K Karikari

Förderung

  • NIA NIH HHS
  • NIH HHS
  • Alzheimer's Association
  • National Institutes of Health
  • Demensförbundet
  • European Commission
  • European Regional Development Fund

Zitieren

APA

Gonzalez-Ortiz, F., Dias, A., Turton, M., Magalhães, R., Kac, P. R., Correia, M., Harrison, P., Zetterberg, H., Maia, L. F., Blennow, K., & Karikari, T. K. (2023). Preanalytical stability of plasma/serum brain‐derived tau. Alzheimer's & Dementia, 19(10), 4764-4770. https://doi.org/10.1002/alz.13156

Vancouver

Gonzalez-Ortiz F, Dias A, Turton M, Magalhães R, Kac PR, Correia M, et al. Preanalytical stability of plasma/serum brain‐derived tau. Alzheimer's & Dementia. 2023;19(10):4764-4770. doi:10.1002/alz.13156

BibTeX
@article{GonzalezOrtiz2023,
  author = {Gonzalez-Ortiz, Fernando and Dias, Alexandre and Turton, Michael and Magalhães, Rui and Kac, Przemysław R and Correia, Manuel and Harrison, Peter and Zetterberg, Henrik and Maia, Luís F and Blennow, Kaj and Karikari, Thomas K},
  title = {Preanalytical stability of plasma/serum brain‐derived tau},
  journal = {Alzheimer's & Dementia},
  year = {2023},
  volume = {19},
  number = {10},
  pages = {4764--4770},
  doi = {10.1002/alz.13156}
}
Kostenlos starten →